FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($0.78), $0.14 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $29.8 million versus the consensus estimate of $36.16 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.